Noto Tatsunori, Anzai Hitoshi, Nemoto Naohiko, Takenaka Hiroki, Sahara Naohiko, Shimizu Takayuki, Yaguchi Tomoyuki, Takaesu Satoru, Samejima Yusuke
Department of Cardiology, SUBARU Health Insurance, Ota Memorial Hospital, Ota, Japan.
J Cardiol Cases. 2022 Nov 18;27(2):56-59. doi: 10.1016/j.jccase.2022.10.002. eCollection 2023 Feb.
We present the case of a 39-year-old pregnant woman who had intrauterine fetal death and imminent uterine rupture and underwent cesarean section. She also underwent catheter embolization for hemorrhagic shock due to bleeding from the uterine artery, and heparin-containing saline was used. On day 7 of hospitalization, she felt severe pain in her right lower leg, and computed tomography (CT) revealed focal nonocclusive thrombus formations in the right common and external iliac artery. After intravenous heparin administration, she suddenly developed dyspnea, her blood pressure dropped, and her platelet count decreased. We diagnosed her with heparin-induced thrombocytopenia (HIT). Although we discontinued heparin and switched to argatroban, CT after 5 days revealed subtotal occlusion of the right iliac artery by a massive thrombus. We performed surgical thrombectomy using a Fogarty catheter, but blood flow was not restored. Therefore, we administered urokinase continuously with catheter-directed thrombolysis (CDT). The thrombus in the iliac artery gradually cleared and was successfully eliminated. However, the patient developed gangrene in her right lower leg, and we decided to perform an above-knee amputation of the right leg. She was discharged with a prosthetic leg and prescribed 15 mg of rivaroxaban per day.
HIT is a known serious side effect of heparin administration, and it can sometimes be fatal. HIT treatment using aggressive thrombectomy procedures may be ineffective since such procedures may accelerate thrombus formation when the coagulation cascade is highly activated. In this case, CDT may have to be considered as the first-line treatment before Fogarty thrombectomy when argatroban therapy fails.
我们报告一例39岁的孕妇,她发生了宫内胎儿死亡且即将发生子宫破裂,随后接受了剖宫产手术。她还因子宫动脉出血导致失血性休克而接受了导管栓塞术,术中使用了含肝素的生理盐水。住院第7天,她感到右小腿剧痛,计算机断层扫描(CT)显示右髂总动脉和外髂动脉有局灶性非闭塞性血栓形成。静脉注射肝素后,她突然出现呼吸困难,血压下降,血小板计数减少。我们诊断她为肝素诱导的血小板减少症(HIT)。尽管我们停用了肝素并改用阿加曲班,但5天后的CT显示右髂动脉被大量血栓几乎完全阻塞。我们使用Fogarty导管进行了手术取栓,但血流未恢复。因此,我们通过导管定向溶栓(CDT)持续给予尿激酶。髂动脉内的血栓逐渐清除并成功消除。然而,患者右小腿发生坏疽,我们决定对其进行右大腿截肢术。她出院时安装了假肢,并每天服用15毫克利伐沙班。
HIT是肝素给药已知的严重副作用,有时可能致命。使用积极的取栓手术治疗HIT可能无效,因为当凝血级联反应高度激活时,此类手术可能会加速血栓形成。在这种情况下,当阿加曲班治疗失败时,在Fogarty取栓术前,CDT可能不得不被视为一线治疗方法。